Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21038
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSkrifvars, Markus B-
dc.contributor.authorFrench, Craig-
dc.contributor.authorBailey, Michael-
dc.contributor.authorPresneill, Jeffrey-
dc.contributor.authorNichol, Alistair-
dc.contributor.authorLittle, Lorraine-
dc.contributor.authorDurantea, Jacques-
dc.contributor.authorHuet, Olivier-
dc.contributor.authorHaddad, Samir-
dc.contributor.authorArabi, Yaseen-
dc.contributor.authorMcArthur, Colin-
dc.contributor.authorCooper, D James-
dc.contributor.authorBellomo, Rinaldo-
dc.date.accessioned2019-06-19T06:29:57Z-
dc.date.available2019-06-19T06:29:57Z-
dc.date.issued2018-
dc.identifier.citationJournal of neurotrauma 2018; 35(2): 333-340-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/21038-
dc.description.abstractThe EPO-TBI study randomized 606 patients with moderate or severe traumatic brain injury (TBI) to be treated with weekly epoetin alfa (EPO) or placebo. Six month mortality was lower in EPO treated patients in an analysis adjusting for TBI severity. Knowledge of possible differential effects by TBI injury subtype and acute neurosurgical treatment as well as timing and cause of death (COD) will facilitate the design of future interventional TBI trials. We defined COD as cerebral (brain death, cerebral death with withdrawal, or death during maximal care) and non-cerebral (death following withdrawal or during maximal care, which had a non-cerebral cause). The study included 305 patients treated with EPO and 297 treated with placebo, with COD recorded in 77 (99%) out of 78 non-survivors. Median time to death in patients dying of cerebral COD was 8 days (interquartile range [IQR] 5-16) compared with 29 days (IQR 7-56) (p = 0.01) for non-cerebral COD. When assessing subgroups by admission CT scan injury findings, we found no significant differential effects of EPO compared with placebo. However, EPO appeared more effective in patients with an injury type not requiring a neurosurgical operation prior to intensive care unit (ICU) admission (odds ratio [OR] 0.29, 95% confidence interval [CI] 0.14-0.61, p = 0.001, p for interaction = 0.003) and in this subgroup, fewer patients died of cerebral causes in the EPO than in the placebo group (5% compared with 14%, p = 0.03). In conclusion, most TBI deaths were from cerebral causes that occurred during the first 2 weeks, and were related to withdrawal of care. EPO appeared to specifically reduce cerebral deaths in the important subgroup of patients with a diffuse type of injury not requiring a neurosurgical intervention prior to randomization.-
dc.language.isoeng-
dc.subjectadult brain injury-
dc.subjectclinical management of central nervous system injury-
dc.subjecthead trauma-
dc.subjecthuman studies-
dc.subjecttraumatic brain injury (TBI)-
dc.titleCause and Timing of Death and Subgroup Differential Effects of Erythropoietin in the EPO-TBI Study.-
dc.typeJournal Article-
dc.identifier.journaltitleJournal of neurotrauma-
dc.identifier.affiliationDivision of Intensive Care, Department of Anaesthesiology, Intensive Care and Pain Medicine, Helsinki University and Helsinki University Hospital, Helsinki, Finlanden
dc.identifier.affiliationDepartment of Intensive Care, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Intensive Care and Hyperbaric Medicine, The Alfred, Melbourne, Victoria, Australiaen
dc.identifier.affiliationSchool of Medicine and Medical Sciences, University College Dublin, Dublin, Irelanden
dc.identifier.affiliationSt Vincent's University Hospital, Dublin, Irelanden
dc.identifier.affiliationDepartment of Intensive Care, Royal Melbourne Hospital, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Intensive Care, Western Health, Melbourne, Victoria, Australiaen
dc.identifier.affiliationNorth West Academic Centre, University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationAustralian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDépartement d'Anesthésie-Réanimation, Hôpital de Bicêtre, Assistance Publique des Hopitaux de Paris, Hôpitaux Universitaires Paris-Sud, Université Paris-Sud, Paris, France-
dc.identifier.affiliationDepartment of Anaesthesiology and Intensive Care Medicine, CHU La Cavale Blanche, Brest, France-
dc.identifier.affiliationKing Saud Bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia-
dc.identifier.affiliationAuckland City Hospital, Auckland, New Zealand-
dc.identifier.doi10.1089/neu.2017.5135-
dc.identifier.orcid0000-0002-1650-8939-
dc.identifier.pubmedid29020866-
dc.type.austinJournal Article-
dc.type.austinMulticenter Study-
dc.type.austinRandomized Controlled Trial-
dc.type.austinResearch Support, Non-U.S. Gov't-
local.name.researcherBellomo, Rinaldo
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
crisitem.author.deptIntensive Care-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Jul 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.